Supporting Information harvested from two mice for each treatment group and embedded in paraffin, sections were stained with hematoxylin and eosin stain. i) Heart, ii) Injection sites, iii) Kidney, iv) Liver. B) Six months post the final immunisation, organs fixed in formalin were harvested from two mice for each treatment group and embedded in paraffin, sections were stained with hematoxylin and eosin stain. i) Heart, ii) Injection sites, iii) Kidney, iv) Liver. (PDF) S4 Fig. End point titer data of terminal sera bleeds. All the mice were administered 100 μL of two vaccine doses at 3 week intervals at the tail base. Group 1 (mouse 1 to 8) received 100 μg oE2 plus 10 μg Quil-A; Group 2 (mouse 1 to 8) received the FD 100 μg oE2 plus 10 μg Quil-A, Group 3 (mouse 1 to 8) received the oE2 nanovaccine (100 μg oE2 adsorbed to 500 μg SV-140), Group 4 (mouse 1 to 8) received the FD oE2 nanovaccine (100 μg oE2 adsorbed to 500 μg SV-140), Group 5 (mouse 1 to 8) received the FD 500 μg SV-140, Group 6 (mouse 1 to 8) was the unimmunised group and did not receive any vaccination. Sera of individual animals were diluted from 1:100 to 1:6400. (PDF)
